<DOC>
	<DOCNO>NCT00004092</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This randomized phase II trial study two different regimen combination chemotherapy compare see well work treat patient high-risk primary stage II stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With High-Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare toxic effect doxorubicin , cyclophosphamide , paclitaxel v cyclophosphamide , thiotepa , carboplatin patient high-risk primary breast cancer . ( Arm I close accural 4/6/2006 . ) - Compare efficacies regimens followed peripheral blood stem cell rescue patient . - Determine efficacy bisphosphonate prevent relapse/metastasis high-dose chemotherapy patient . OUTLINE : This randomize study . Patients stratified stage disease . Peripheral blood stem cell ( PBSC ) collect mobilization filgrastim ( G-CSF ) , administer subcutaneously IV , twice daily begin 3 day collection continue collection complete . All patient receive conventional-dose adjuvant chemotherapy , probably comprise doxorubicin IV , cyclophosphamide IV , fluorouracil IV 1 hour day 1 , 22 , 43 , 64 . Patients randomize receive 1 2 treatment arm high-dose chemotherapy . ( Arm I close accrual 4/6/2006 . ) - Arm I ( ACT ) ( close accrual 4/6/2006 ) : Patients receive doxorubicin IV 24 hour day -9 -6 , cyclophosphamide IV 2 hour day -5 , paclitaxel IV 24 hour day -2 . PBSC reinfused day -2 0 . G-CSF administered beginning day 0 continue blood count recover . - Arm II ( STAMP V ) : Patients receive cyclophosphamide IV , carboplatin IV , thiotepa IV 24 hour day -7 -4 . PBSC reinfused G-CSF administer arm I . Within 4-6 week day 0 high-dose chemotherapy , patient estrogen and/or progesterone receptor positive tumor receive oral tamoxifen twice daily 5 year . Patients also randomize receive bisphosphonate comprise pamidronate IV every 4 week 2 year . Quality life assess therapy , 30 day high-dose chemotherapy , 6 12 month . Patients follow every 3 month 1 year every 6 month least 10 year . PROJECTED ACCRUAL : A total 100 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven highrisk primary breast cancer le 60 % chance progressionfree survival 3 year diagnosis Stage II least 10 positive axillary node OR Stage IIIA IIIB No histologically proven bone marrow metastasis No CNS metastasis Hormone receptor status : Hormone receptor status know PATIENT CHARACTERISTICS : Age : Physiological age 60 Menopausal status : Not specify Performance status : Karnofsky 80100 % Life expectancy : See Disease Characteristics Hematopoietic : Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time upper limit normal Hepatitis B antigen negative Renal : Creatinine great 1.2 mg/dL Creatinine clearance least 70 mL/min No prior hemorrhagic cystitis Cardiovascular : Ejection fraction least 55 % MUGA No prior significant valvular heart disease arrhythmia Pulmonary : FEV_1 least 60 % predict pO_2 least 85 mm Hg room air pCO_2 least 43 mm Hg room air DLCO least 60 % low limit predict Other : No prior malignancy except squamous cell basal cell skin cancer stage I carcinoma situ cervix No CNS dysfunction would preclude compliance HIV negative No sensitivity E. coliderived product Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy No prior doxorubicin total dose exceed 240 mg/m^2 No prior paclitaxel total dose least 750 mg/m^2 No 12 month since prior conventionaldose adjuvant chemotherapy Endocrine therapy : At least 4 week since prior hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy No prior radiation leave chest wall Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>